Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706248 · ClinicalTrials.gov registry record
Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL
A clinical trial, sponsored by Clinical Genomics Pathology.
- Completed
- Registry status
- 65
- Enrollment target
NCT03706248: Completed study, sponsored by Clinical Genomics Pathology.
NCT03706248 is a clinical trial that has completed, run by Clinical Genomics Pathology. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03706248 has completed, sponsored by Clinical Genomics Pathology.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in subjects with colorectal cancer that have documented recurrence or no evidence of recurrence by CT.
Primary Outcome
Comparison of Colvera and CEA in recurrent and non-recurrent CRC
Interventions
- OTHER Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-07-28 |
| Est. Completion | 2019-07-15 |
What the finished NCT03706248 record still lists
NCT03706248 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Draw is the first listed.
NCT03706248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03706248 about?
NCT03706248 is a clinical study titled "Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL". To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in subjects with colorectal cancer that have documented recurrence or no evidence of recurrence by CT.
What is the current status of trial NCT03706248?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2018-07-28. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT03706248?
The interventions under investigation include: Blood Draw (OTHER).
Who is sponsoring clinical trial NCT03706248?
This trial is sponsored by Clinical Genomics Pathology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI